Entity

Time filter

Source Type


Wendt B.,European Molecular Biology Laboratory EMBL | Wendt B.,ELARA Pharmaceuticals | Uhrig U.,Tripos International | Bos F.,Tripos International
Journal of Chemical Information and Modeling | Year: 2011

Modeling off-target effects is one major goal of chemical biology, particularly in its applications to drug discovery. Here, we describe a new approach that allows the extraction of structure-activity relationships from large chemogenomic spaces starting from a single chemical structure. Several public source databases, offering a vast amount of data on structure and activity for a large number of different targets, have been investigated for their usefulness in automated structure-activity relationships (SAR) extraction. SAR tables were constructed by assembling similar structures around each query structure that have an activity record for a particular target. Quantitative series enrichment analysis (QSEA) was applied to these SAR tables to identify trends and to transform these trends into topomer CoMFA models. Overall more than 1700 SAR tables with topomer CoMFA models have been obtained from the ChEMBL, PubChem, and ChemBank databases. These models were able to highlight the structural trends associated with various off-target effects of marketed drugs, including cases where other structural similarity metrics would not have detected an off-target effect. These results indicate the usefulness of the QSEA approach, particularly whenever applicable with public databases, in providing a new means, beyond a simple similarity between ligand structures, to capture SAR trends and thereby contribute to success in drug discovery. © 2011 American Chemical Society. Source


ELARA Pharmaceuticals | Entity website

! 2018 2018 14 2 (CAT3) 105 2 15 (CAT1) 1,100 110 11 1,280 20 2010 2018 2018 c 2017 ( 8 )


! 2 +- 34 , , 18 6 2016 16 34 18 34 18 2 MUTV 18 34


ELARA Pharmaceuticals | Entity website

Posted by admin On - 9 - 2016


Toner A.P.,National University of Ireland | McLaughlin F.,ELARA Pharmaceuticals | Giles F.J.,National University of Ireland | Sullivan F.J.,National University of Ireland | And 8 more authors.
British Journal of Cancer | Year: 2013

Background:Taxanes are routinely used for the treatment of prostate cancer, however the majority of patients eventually develop resistance. We investigated the potential efficacy of EL102, a novel toluidine sulphonamide, in pre-clinical models of prostate cancer.Methods:The effect of EL102 and/or docetaxel on PC-3, DU145, 22Rv1 and CWR22 prostate cancer cells was assessed using cell viability, cell cycle analysis and PARP cleavage assays. Tubulin polymerisation and immunofluorescence assays were used to assess tubulin dynamics. CWR22 xenograft murine model was used to assess effects on tumour proliferation. Multidrug-resistant lung cancer DLKPA was used to assess EL102 in a MDR1-mediated drug resistance background.Results:EL102 has in vitro activity against prostate cancer, characterised by accumulation in G2/M, induction of apoptosis, inhibition of Hif1, and inhibition of tubulin polymerisation and decreased microtubule stability. In vivo, a combination of EL102 and docetaxel exhibits superior tumour inhibition. The DLKP cell line and multidrug-resistant DLKPA variant (which exhibits 205 to 691-fold greater resistance to docetaxel, paclitaxel, vincristine and doxorubicin) are equally sensitive to EL102.Conclusion:EL102 shows potential as both a single agent and within combination regimens for the treatment of prostate cancer, particularly in the chemoresistance setting. © 2013 Cancer Research UK. All rights reserved. Source

Discover hidden collaborations